expanded access

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

Leave a Comment / Blogger, Uncategorized / By

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

New HIV Drugs in the Pipeline – 2012

Leave a Comment / Blogger, Uncategorized / By

Gilead has completed and released 48-week data from ongoing phase 3 studies of a four-drug fixed dose combination (elvitegravir, cobicistat, tenofovir, and FTC- called QUAD), as it has with studies of the integrase inhibitor elvitegravir and the pharmacokinetic booster cobicistat.  QUAD  will likely be approved for treatment naive patients after August this year.  Results from …

New HIV Drugs in the Pipeline – 2012 Read More »

Is There a Future for HIV-Infected Patients in “Deep Salvage”?

Leave a Comment / Blogger, Uncategorized / By

Print this page    •   Back to Web version of article By Nelson Vergel, B.S.Ch.E., M.B.A. May 3, 2011 “Only patients who do not take their medications as prescribed have multidrug resistance.” “Deep salvage patients no longer exist. The ones in that situation are already dead or have responded to the latest HIV antiretrovirals.” “Even if we give …

Is There a Future for HIV-Infected Patients in “Deep Salvage”? Read More »

Dolutegravir, Trii and new abacavir data- How it all ties together

Leave a Comment / Blogger, Uncategorized / By

By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took …

Dolutegravir, Trii and new abacavir data- How it all ties together Read More »

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options

Leave a Comment / Blogger, Uncategorized / By

Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »